![Western Blot: KPNA3 Antibody [NB100-81650] - Association of NCBP3 and NCBP2 with NCBP1 and proteins involved in RNA processing. Western blot analysis of representative GFP-precipitated proteins identified by AP-MS analysis. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms9192), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/KPNA3-Antibody-Western-Blot-NB100-81650-img0004.jpg "Western Blot: KPNA3 Antibody [NB100-81650] - Association of NCBP3 and NCBP2 with NCBP1 and proteins involved in RNA processing. Western blot analysis of representative GFP-precipitated proteins identified by AP-MS analysis. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms9192), licensed under a CC-BY license.")
| Reactivity | HuSpecies Glossary |
| Applications | WB, IHC, IP |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Concentration | 0.2 mg/ml |
| Immunogen | The immunogen recognized by this antibody maps to a region between residue 1 and 50 of human karyopherin alpha 3 using the numbering given in entry NP_002258.2 (GeneID 3839). |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | KPNA3 |
| Purity | Immunogen affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
||
| Application Notes | Epitope retrieval with citrate buffer pH6.0 is recommended for FFPE tissue sections. |
||
| Theoretical MW | 58 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
||
| Control |
|
||
| Publications |
|
| Storage | Store at 4C. Do not freeze. |
| Buffer | TBS and 0.1% BSA |
| Preservative | 0.09% Sodium Azide |
| Concentration | 0.2 mg/ml |
| Purity | Immunogen affinity purified |
Secondary Antibodies |
Isotype Controls |
Research Areas for KPNA3 Antibody (NB100-81650)Find related products by research area.
|
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
![Immunohistochemistry-Paraffin: KPNA3 Antibody [NB100-81650] - Human prostate carcinoma. Antibody used at a dilution of 1:200.](http://images.novusbio.com/fullsize/KPNA3-Antibody-Immunohistochemistry-Paraffin-NB100-81650-img0003.jpg "Immunohistochemistry-Paraffin: KPNA3 Antibody [NB100-81650] - Human prostate carcinoma. Antibody used at a dilution of 1:200.")
![Western Blot: KPNA3 Antibody [NB100-81650] - Whole cell lysate from HeLa (5, 15 and 50 mcg for WB; 1 mg for IP, 20% of IP loaded) and 293T (T; 50 mcg) cells. NB100-81650 used for WB at 0.4 mcg/ml (A and B) and used for IP at 3 mcg/mg lysate.](http://images.novusbio.com/fullsize/KPNA3-Antibody-Western-Blot-NB100-81650-img0002.jpg "Western Blot: KPNA3 Antibody [NB100-81650] - Whole cell lysate from HeLa (5, 15 and 50 mcg for WB; 1 mg for IP, 20% of IP loaded) and 293T (T; 50 mcg) cells. NB100-81650 used for WB at 0.4 mcg/ml (A and B) and used for IP at 3 mcg/mg lysate.")
![Western Blot: KPNA3 Antibody [NB100-81650] - DZNep suppressed MPNST724 xenograft tumor initiation & growthin vivo. (A) MPNST724 xenograft tumor groups treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep 13 weeks after subcutaneous injection (n = 9 mice per group). (B) Growth curves of tumors treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep over a period of 13 weeks. Mean ± SD values are shown; *p < 0.05, Student t test. (C) Western blot analyses of EZH2, KPNB1, & actin in tumor MPNST samples treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep. Image collected & cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0325-1), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-81650_rabbit-polyclonal-kpna3-antibody-310202415392575.jpg "Western Blot: KPNA3 Antibody [NB100-81650] - DZNep suppressed MPNST724 xenograft tumor initiation & growthin vivo. (A) MPNST724 xenograft tumor groups treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep 13 weeks after subcutaneous injection (n = 9 mice per group). (B) Growth curves of tumors treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep over a period of 13 weeks. Mean ± SD values are shown; *p < 0.05, Student t test. (C) Western blot analyses of EZH2, KPNB1, & actin in tumor MPNST samples treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep. Image collected & cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0325-1), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: KPNA3 Antibody [NB100-81650] - DZNep inhibited EZH2/miR-30d/KPNB1 signaling in MPNST cells. (A) Western blot analyses of EZH2, cleaved PARP (cPARP), KPNB1, & GAPDH (loading control) in MPNST724 & S462 cells treated with DZNep at increasing concentrations for 48 hours. (B) qRT-PCR analyses of miR-30d expression in MPNST724 & S462 cells treated with DZNep for 96 hours. miR-30d expression was normalized to SNORD47. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (C) Promoter activity assay showed that DZNep treatment increased miR-30d promoter activity in S462 cells. Mean ± SD values are shown (n = 3); *p < 0.05; Student t test. (D) Luciferase reporter assay showed that DZNep treatment inhibited miR-30d target reporter activity in S462 cells. Mean ± SD values are shown (n = 3); **p < 0.01, Student t test. (E) Luciferase reporter assay indicated that DZNep treatment inhibited wild-type (WT) KPNB1 3’UTR reporter activity but not mutant (MT) KPNB1 3’UTR reporter activity in S462 cells. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. Image collected & cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0325-1), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-81650_rabbit-polyclonal-kpna3-antibody-310202415532089.jpg "Western Blot: KPNA3 Antibody [NB100-81650] - DZNep inhibited EZH2/miR-30d/KPNB1 signaling in MPNST cells. (A) Western blot analyses of EZH2, cleaved PARP (cPARP), KPNB1, & GAPDH (loading control) in MPNST724 & S462 cells treated with DZNep at increasing concentrations for 48 hours. (B) qRT-PCR analyses of miR-30d expression in MPNST724 & S462 cells treated with DZNep for 96 hours. miR-30d expression was normalized to SNORD47. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (C) Promoter activity assay showed that DZNep treatment increased miR-30d promoter activity in S462 cells. Mean ± SD values are shown (n = 3); *p < 0.05; Student t test. (D) Luciferase reporter assay showed that DZNep treatment inhibited miR-30d target reporter activity in S462 cells. Mean ± SD values are shown (n = 3); **p < 0.01, Student t test. (E) Luciferase reporter assay indicated that DZNep treatment inhibited wild-type (WT) KPNB1 3’UTR reporter activity but not mutant (MT) KPNB1 3’UTR reporter activity in S462 cells. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. Image collected & cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0325-1), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: KPNA3 Antibody [NB100-81650] - EZH2-regulated miR-30a targeted KPNB1 in MPNST cells. (A) Putative miR-30a & miR-30d target site in the wild-type KPNB1 3’UTR region. (B) qRT-PCR analyses of miR-30a in MPNST724 & S462 cells transfected with a negative control or EZH2 siRNA. miR-30a expression was normalized to SNORD47. Data are shown as mean ± SD (n = 3); *p < 0.05, Student t test. (C) qRT-PCR analyses of miR-30a in S462 & MPNST724 cells treated with DZNep for 96 hours. miR-30d expression was normalized to SNORD47. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (D) Western blot analyses of KPNB1 & actin in S462 & MPNST724 cells transfected with a negative control (Ctl) or miR-30a (30a) mimics. (E) Luciferase reporter assay showed that miR-30a inhibited wild-type (WT) KPNB1 3’UTR reporter activity but not mutant (MT) KPNB1 3’UTR reporter activity in S462 cells. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (F) qRT-PCR analyses of miR-30a expression in normal Schwann cells (NSC) & multiple MPNST cell lines (MPNST724, S462, STS26T, MPNST624, T265, & ST88-14). Image collected & cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0325-1), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-81650_rabbit-polyclonal-kpna3-antibody-310202416284927.jpg "Western Blot: KPNA3 Antibody [NB100-81650] - EZH2-regulated miR-30a targeted KPNB1 in MPNST cells. (A) Putative miR-30a & miR-30d target site in the wild-type KPNB1 3’UTR region. (B) qRT-PCR analyses of miR-30a in MPNST724 & S462 cells transfected with a negative control or EZH2 siRNA. miR-30a expression was normalized to SNORD47. Data are shown as mean ± SD (n = 3); *p < 0.05, Student t test. (C) qRT-PCR analyses of miR-30a in S462 & MPNST724 cells treated with DZNep for 96 hours. miR-30d expression was normalized to SNORD47. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (D) Western blot analyses of KPNB1 & actin in S462 & MPNST724 cells transfected with a negative control (Ctl) or miR-30a (30a) mimics. (E) Luciferase reporter assay showed that miR-30a inhibited wild-type (WT) KPNB1 3’UTR reporter activity but not mutant (MT) KPNB1 3’UTR reporter activity in S462 cells. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (F) qRT-PCR analyses of miR-30a expression in normal Schwann cells (NSC) & multiple MPNST cell lines (MPNST724, S462, STS26T, MPNST624, T265, & ST88-14). Image collected & cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0325-1), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")